Plain-English translation of NCT05336383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , given after BCMA CAR-T cell therapy, can help patients whose multiple myeloma has come back or is no longer responding to standard treatment. BCMA CAR-T cell therapy is a type of personalized cell treatment that trains your own immune cells to fight cancer. The study wants to see if adding targeted radiation to specific cancer spots in your bones or tissues can improve how well the treatment works.
Some patients receive this medication but still have active cancer afterward. Researchers believe that adding to specific areas of remaining disease might help the treatment work better and give patients more time before needing additional chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will receive targeted aimed at specific areas of your remaining cancer, typically to up to five different treatment sites. The radiation doses will be carefully planned by your care team. Throughout the study, researchers will monitor your health, take blood samples, and possibly collect tissue samples to understand how your immune system is responding to the combination of the cell therapy and radiation.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States